A Randomised, Double-blind, Parallel Group, Roll-over Study Evaluating Long-term Safety and Efficacy of Oral Doses of BI 1291583 q.d. in Patients With Bronchiectasis (Clairleafᵀᴹ)
Latest Information Update: 08 Apr 2025
At a glance
- Drugs BI 1291583 (Primary)
- Indications Bronchiectasis
- Focus Adverse reactions
- Acronyms ClairleafTM
- Sponsors Boehringer Ingelheim
Most Recent Events
- 03 Apr 2025 Planned End Date changed from 30 Mar 2026 to 31 Mar 2027.
- 03 Apr 2025 Planned primary completion date changed from 2 Mar 2026 to 31 Mar 2027.
- 11 Dec 2024 Status changed from recruiting to active, no longer recruiting.